The VOICE Study – Vaginal and Oral Interventions to Control the Epidemic – was designed to evaluate the safety and effectiveness of two antiretroviral (ARV)-based approaches for preventing sexual transmission of HIV in women as well as determining which of these women are more likely to follow: applying vaginal gel (tenofovir gel) daily or taking an ARV tablet (tenofovir or Truvada®) once a day. VOICE also includes two sub-studies: VOICE B (Bone Mineral Density) and VOICE C (Household and Community Factors Associated with Adherence).
The oral tenofovir and tenofovir gel arms of VOICE were dropped following interim reviews of data that determined neither product was effective in the women assigned to those study groups. Truvada continues to be evaluated. The study is expected to be completed in August 2012 and final results to be reported early 2013.
Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study
Mar 4, 2013
VOICE Fact Sheet – Understanding the Results of VOICE
Mar 4, 2013
Mar 4, 2013
Anticipating the Results of VOICE
Dec 12, 2012
Nov 18, 2012
Nov 25, 2011
Questions and Answers on Decision to Modify VOICE, Outcome of November 17 DSMB Review
Nov 25, 2011
VOICE B (Bone Mineral Density Sub-study)
Apr 5, 2012
Please note that the information contained in the following news releases and materials may have changed since publication.
Sep 28, 2011
Questions and Answers on Decision to Modify VOICE, Outcome of September 16 DSMB Review
Sep 28, 2011
Questions and Answers about the CDC TDF2 Study and VOICE
Jul 14, 2011
VOICE Study will Continue as it Considers What Action to Take After Results of Two Trials
Jul 13, 2011
Questions and Answers about Partners PrEP and VOICE
Jul 13, 2011
HIV Prevention Trial Milestone: VOICE Study Completes Enrollment of 5,000 Women
Jun 6, 2011
Apr 18 2011
Nov 23, 2010
Results of CAPRISA 004 a turning point for HIV prevention, say MTN researchers conducting VOICE
Jul 19, 2010
VOICE Study, a major HIV prevention trial for women, is launched in Zimbabwe
Sep 16, 2009
NIAID Press Release on start of VOICE
Sep 16, 2009
HIV prevention trial of ARV-based strategies to begin next month
Jul 20, 2009
VOICE B (Bone Mineral Density Sub-study)
VOICE C (Community and Adherence Sub-study)
Understanding Resistance
Drug Resistance and ARV-Based Prevention Fact Sheet
Drug Resistance and ARV-Based Prevention Q&A
Diagrams:
Video: Drug Resistance and ARV-Based Prevention
See Also
Understanding the Results of iPrEx
Understanding the Results of CAPRISA 004
Pre-Exposure Prophylaxis (PrEP) Fact Sheet
MTN-003 (VOICE) Study Protocol
MTN-003 B (VOICE B) Study Protocol
MTN-003 C (VOICE C) Study Protocol
